NanoTess is set to distribute its flagship product to more than 14,000 pharmacies across Canada.
The Calgary-based startup, an innovator in skin and wound care solutions, is known for NanoSALV Catalytic.
NanoSALV Catalytic heals wounds faster and is an effective early intervention and remedial treatment for diabetic foot ulcers, venous leg ulcers, and hard-to-heal wounds, according to a statement from the company—ailments which NanoTess says impact Canadians living with diabetes or pre-diabetes.
“Our goal with NanoTess was to create a product that could be used by a person as well as a healthcare system,” says Megan Leslie, chief executive officer of NanoTess. “Reducing barriers to care has always been our highest priority as a company.”
NanoTess signed a distribution agreement for NanoSALV Catalytic with embecta, which supplies insulin injection devices to 30 million people in over 100 countries.
NanoSALV Catalytic is the first wound care product to be distributed by embecta in Canada.
More than four million adults in Canada live with diabetes, and this population is 20 times more likely to undergo non-traumatic lower limb amputations.
In 2024, the cost of diabetes care in Canada was more than $18 billion.
The partnership with embecta lowers healthcare barriers “by making catalytic wound care accessible to every Canadian living with diabetes and every Canadian living with wound and skin concerns,” according to Leslie.
Awareness and education “within the diabetes community have never been higher and demand for easy-to-use, early intervention treatments for concerns such as wounds has been clear for some time now,” suggests Jennifer Spearen, who functions as general manager of embecta Canada. “NanoSALV Catalytic is all those things and it was developed and produced right here in Canada.”
The award-winning NanoTess was founded in 2020 by Leslie and Julian Mulia to help “prevent unnecessary suffering” after Mulia lost both parents to chronic health conditions in 2019.
Leave a Reply